Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03323320
Other study ID # AOD
Secondary ID
Status Completed
Phase N/A
First received October 24, 2017
Last updated February 26, 2018
Start date December 5, 2016
Est. completion date November 1, 2017

Study information

Verified date February 2018
Source Groupe Hospitalier Paris Saint Joseph
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

More than one million of patient receive anti vitamine K treatment which is the main cause of hospitalization. About 50 000 patient receive direct oral anticoagulant .

The aim is to evaluate the patient's level of knowledge about their anticoagulant treatment and specially about the side effect


Recruitment information / eligibility

Status Completed
Enrollment 51
Est. completion date November 1, 2017
Est. primary completion date March 31, 2017
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- patient with AOD treatment

- capable to answer to questionnaire

- with or without antivitamin K

Exclusion Criteria:

- dementia

- cognitive trouble

- refusing participation

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
France Groupe Hospitalier Paris Saint Joseph Paris Ile-de-France

Sponsors (1)

Lead Sponsor Collaborator
Groupe Hospitalier Paris Saint Joseph

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary questionnaire score >80% it's a questionnaire about anticoagulant treatment ; each question has a score ans for the study investigators calculate the total Day 1
See also
  Status Clinical Trial Phase
Recruiting NCT04010955 - Adding Antiplatelet During Edoxaban Treatment in Stroke Patients With Non-valvular Atrial Fibrillation (ADD-ON)
Recruiting NCT04673695 - A Clinical Study to Evaluate the Safety and Pharmacokinetics of CKD-344 Phase 1
Completed NCT03893591 - A Prospective Study to Examine the Need to Adjust the Dose of Apixaban When Used in Atrial Fibrillation and Obesity
Completed NCT03895502 - Optimal Duration of Anticoagulation Therapy for Isolated Distal Deep Vein Thrombosis in Patients With Cancer Study Phase 4
Completed NCT03154489 - Effectiveness of a Multidisciplinary Medication Review With Follow-up for Patients Treated With Coumarin Anticoagulants in Primary Care N/A
Completed NCT04305821 - Medico-economic Interest of the Protein S100b in Mild Head Trauma Under Anti-thrombotics
Recruiting NCT06020560 - Study of Low Molecular Weight Heparins Phase 4
Not yet recruiting NCT05788913 - Evaluation of the Pharmacodynamics of a Heparin With Its Biological Comparator, Subcutaneous Administration Phase 1
Not yet recruiting NCT05788900 - Evaluation of the Pharmacodynamics of a Heparin With Its Biological Comparator, Intravenous Administration Phase 1
Terminated NCT03172546 - Determinants of Oral Anticoagulants' Activity
Not yet recruiting NCT04592822 - A Single Dose Bioequivalence Study of WD-1602 Versus Pradaxa® in Healthy Subjects Under Fed Condition Phase 1
Recruiting NCT03772457 - Predictive Value of Infarction Volume on Hemorrhagic Transformation in Ischemic Stroke/TIA With Non-valve Atrial Fibrillation(NVAF) Patients Using Rivaroxaban
Recruiting NCT04257487 - Sulodexide, VESSEL®, for the Prevention of Recurrent Venous Thromboembolism (The Jason Study) Phase 3
Completed NCT04272723 - Management of Venous Thromboembolism in France: a National Survey Among Vascular Medicine Physicians
Recruiting NCT04867200 - A Clinical Study to Evaluate the Safety and Pharmacokinetics of CKD-344 in Healthy Volunteers Phase 1